Belarus Pharmaceuticals and Healthcare Report Q1 2015

Business Monitor International
December 17, 2014
87 Pages - SKU: BMI5416294
Countries covered: Belarus

Belarus Pharmaceuticals and Healthcare Report Q1 2015

BMI View: The Belarusian market will suffer from the impact of depreciation and economic instability asthe country's economy becomes ever more reliant on Russian loans to function. Furthermore, wage growthmandated by the government will become unsustainable, threatening to dampen internal consumption.

Belarus will present little reward for high risk for most pharmaceutical companies in the region.

Headline Expenditure Projections

Pharmaceuticals: BYR8,927bn in 2013 (USD1.00bn) to BYR11,490bn (USD1.09bn) in 2014; +28.7% inlocal currency terms and +9.2% in US dollar terms.

Healthcare: BYR29,768bn (USD3.34bn) in 2013 to BYR37,249bn (USD3.55bn) in 2014; +25.1% in localcurrency terms and +6.1% in US dollar terms.



More Prescription Drugs reports by Business Monitor International

Namibia Pharmaceuticals and Healthcare Report Q1 2015 by Business Monitor International
Namibia Pharmaceuticals and Healthcare Report Q1 2015BMI View: Recent comments by the public relations officer of the Ministry of Health and Social Services,Ester Paulus, that ...
Moldova Pharmaceuticals and Healthcare Report Q1 2015 by Business Monitor International
Moldova Pharmaceuticals and Healthcare Report Q1 2015BMI View: The Moldovan pharmaceutical market presents limited opportunities for investors in the shortterm, but with the country opening ...
Ghana Pharmaceuticals and Healthcare Report Q1 2015 by Business Monitor International
Ghana Pharmaceuticals and Healthcare Report Q1 2015BMI View: We anticipate that the continuing roll-out of biometric registration and expansion of thecommunity-based health planning and services ...
Central America Pharmaceuticals and Healthcare Report Q1 2015 by Business Monitor International
Central America Pharmaceuticals and Healthcare Report Q1 2015BMI View: Central America will continue to offer revenue-generating opportunities for multinationalpharmaceutical companies. An ageing population, favourable tax ...
See all reports like this >>

More Belarus Prescription Drugs reports

Pharmaceuticals and Healthcare Report - Belarus Q4 2014 by Business Monitor International
Pharmaceuticals and Healthcare Report - Belarus Q4 2014BMI View: The Belarusian market will suffer from the impact of prolonged rouble depreciation andeconomic instability. ...
Belarus Pharmaceuticals and Helathcare Report Q3 2012 by Business Monitor International
BMI View: The short-term outlook for the Belarusian pharmaceutical market is deeply uncertain due toexchange-rate volatility and the economy’s lack of capacity for progress without ...
See all reports like this >>

 

SELECT A LICENSE

    Report with 3 quarterly updates  USD 1,295  
    Report with 3 quarterly updates
3 User License
  USD 1,945  
    Report with 3 quarterly updates
5 User License
  USD 2,500  
    Report with 3 quarterly updates
Departmental/Site License
  USD 2,995  
    Global Site License Fulfilled by Publisher  USD 6,995  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!